ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Single-Dose Anti-Thymocyte Globulin is Non-Inferior to Divided-Dose for Induction Therapy in Kidney and Pancreas Transplantation

A. I. Ingemi1, O. F. Bangash1, S. McCoy1, L. Hulse2, J. Colonna1, H. Sadr1, S. Sutton1, M. Coleman1, T. Wilson1, T. R. McCune1

1Sentara Norfolk General Hospital, Norfolk, VA, 2Children's Hospital of the King's Daughters, Norfolk, VA

Meeting: 2020 American Transplant Congress

Abstract number: 9

Keywords: Induction therapy, Kidney/pancreas transplantation

Session Information

Session Name: Kidney Immunosuppression: Induction Therapy

Session Type: Oral Abstract Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:45pm

 Presentation Time: 4:03pm-4:15pm

Location: Virtual

*Purpose: Emerging studies suggest that single-dose rabbit antithymocyte globulin (rATG) is not inferior to the divided-dose, however this dosing strategy has never been evaluated in a cohort of primarily African American patients or pancreas transplant patients. The aim of the study was to compare the efficacy and safety of single-dose (SD) rATG to divided-dose (DD) rATG for induction in both renal and pancreatic transplant patients.

*Methods: This retrospective crossover study evaluated patients prior to and after the initiation of a SD rATG protocol. All patients who received rATG were included in the study and were maintained with standard immunosuppression of tacrolimus, mycophenolate, and steroids. The dose of rATG was the same between groups, with the SD rATG receiving 6mg/kg in 24 hours while the DD rATG received 1.5mg/kg daily for four days. The primary end-point was rejection at 1 year.

*Results: In the 199 patients included (99 DD/100 SD, 74% African American, 7% pancreas transplant, 94% kidney transplant), there was no difference in rejection at 1 year (11% vs. 11%, p = 0.98). There was also no difference in delayed graft function, serum creatinine or survival at 1 year (p = 0.192, p = 0.501, and p = 0.621). For the pancreas transplant patients (n=13), there was no difference in fasting glucose, amylase or lipase at 1 year. Patients in the SD group were more likely to receive the entire prescribed dose of rATG (5.92mg/kg vs. 5.55mg/kg, p = 0.009). Initially, the SD group had more leukopenia and thrombocytopenia, however thrombocytopenia resolved by post-operative day 4 and leukopenia resolved by 3 months. Patients were more likely to leave the hospital by post-operative day 3 in the SD group (12% vs. 2%, p= 0.006). There was no difference in readmission at 30 days (36% vs. 31%, p = 0.484) or at 1 year (75% vs. 67%, p = 0.196). At one year, more patients in the SD group developed CMV-emia than the DD group (44% vs. 29%, p = 0.031), however there were no differences in other infections.

*Conclusions: Use of single dose rabbit anti thymocyte globin 6 mg/kg over 24 hours is an acceptable alternative to the standard divided-dose for induction therapy in kidney and pancreas transplant in a predominantly African American population. This regimen has the potential to decrease hospital length of stay without increasing hospital 30-day readmission.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Ingemi AI, Bangash OF, McCoy S, Hulse L, Colonna J, Sadr H, Sutton S, Coleman M, Wilson T, McCune TR. Single-Dose Anti-Thymocyte Globulin is Non-Inferior to Divided-Dose for Induction Therapy in Kidney and Pancreas Transplantation [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/single-dose-anti-thymocyte-globulin-is-non-inferior-to-divided-dose-for-induction-therapy-in-kidney-and-pancreas-transplantation/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences